To determine whether an β2AR agonist would improve clinical outcomes in patients with ALI, a multi‐centre, phase III randomized, placebo‐controlled clinical trial was conducted among the patients receiving aerosolized albuterol or saline every 4 h for up to 10 days. The gene discussed is ADRB2; the disease is acute respiratory distress syndrome.